$0.15
+0.01 (+3.57%)
Open$0.15
Previous Close$0.14
Day High$0.15
Day Low$0.15
52W High$1.48
52W Low$0.05
Volume—
Avg Volume48.1K
Market Cap2.49M
P/E Ratio—
EPS$-2.81
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+27,575.9% upside
Current
$0.15
$0.15
Target
$40.13
$40.13
$29.11
$40.13 avg
$50.28
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 31.91M | 32.51M | 9.51M |
| Net Income | -43,899,281 | -40,249,952 | 434.3K |
| Profit Margin | -137.6% | -130.7% | 4.6% |
| EBITDA | -44,285,235 | -42,859,589 | 716.5K |
| Free Cash Flow | — | — | 350.1K |
| Rev Growth | -1.8% | -1.8% | +3.9% |
| Debt/Equity | 9.93 | 9.93 | 0.38 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |